12 Month Price Forecast For VIR
Distance to VIR Price Forecasts
VIR Price Momentum
🤔 Considering Vir Biotechnology (VIR)?
Join 5,000+ investors getting our exclusive market analysis every Monday & Thursday. Stay ahead of breakout opportunities.
Disclaimer: The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Data last updated: January 23, 2025 5:56 AM UTC
VIR Analyst Ratings & Price Targets
Based on our analysis of 14 Wall Street analysts, VIR has a consensus that is bullish. The median price target is $20.00, with forecasts ranging from $14.00 to $110.00. Currently, there are 7 Buy ratings, 2 Hold ratings, and 0 Sell ratings.
With VIR currently trading at $10.53, the median price forecast suggests a 89.9% upside. The most optimistic forecast comes from Patrick Trucchio at HC Wainwright & Co., projecting a 944.6% upside, while Eric Joseph at JP Morgan provides the most conservative target, suggesting a 33.0% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
VIR Analyst Consensus
VIR Price Target Range
Latest VIR Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for VIR.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Jan 13, 2025 | Leerink Partners | Roanna Ruiz | Outperform | Maintains | $20.00 |
| Jan 10, 2025 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $110.00 |
| Jan 9, 2025 | Morgan Stanley | Michelle Gilson | Overweight | Upgrade | $20.00 |
| Jan 9, 2025 | JP Morgan | Eric Joseph | Neutral | Maintains | $14.00 |
| Nov 20, 2024 | Needham | Joseph Stringer | Buy | Reiterates | $19.00 |
| Nov 20, 2024 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $110.00 |
| Nov 4, 2024 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $110.00 |
| Nov 4, 2024 | Barclays | Gena Wang | Overweight | Maintains | $26.00 |
| Nov 1, 2024 | Needham | Joseph Stringer | Buy | Reiterates | $19.00 |
| Aug 20, 2024 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $110.00 |
| Aug 2, 2024 | Barclays | Gena Wang | Overweight | Maintains | $28.00 |
| Jun 6, 2024 | Morgan Stanley | Michelle Gilson | Equal-Weight | Maintains | $15.00 |
| Jun 5, 2024 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $110.00 |
| Jun 5, 2024 | Needham | Joseph Stringer | Buy | Maintains | $19.00 |
| May 24, 2024 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $110.00 |
| May 7, 2024 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $110.00 |
| May 3, 2024 | JP Morgan | Eric Joseph | Neutral | Maintains | $12.00 |
| May 3, 2024 | Needham | Joseph Stringer | Buy | Reiterates | $15.00 |
| Mar 15, 2024 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $110.00 |
| Feb 23, 2024 | JP Morgan | Eric Joseph | Neutral | Maintains | $10.00 |
Stocks Similar to Vir Biotechnology Inc
The following stocks are similar to Vir Biotechnology based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Vir Biotechnology Inc (VIR) Financial Data
Vir Biotechnology Inc has a market capitalization of $1.44B with a P/E ratio of -2.3x. The company generates $78.62M in trailing twelve-month revenue with a 93.0% profit margin.
Revenue growth is -9.8% quarter-over-quarter, while maintaining an operating margin of -9,184.5% and return on equity of -36.6%.
Valuation Metrics
Growth & Margins
Financial Health
🔥 Want More High-Potential Stock Ideas?
Join 5,000+ investors getting our research on stocks with massive upside potential.
Vir Biotechnology Inc (VIR) Company Overview
About Vir Biotechnology Inc
Develops therapies for serious infectious diseases.
The company operates by developing therapeutic products aimed at treating and preventing serious infectious diseases. It generates revenue through a combination of grant agreements, collaborative research, licensing deals, and partnerships with various organizations, including prominent foundations and pharmaceutical companies.
Vir Biotechnology has a robust pipeline targeting multiple viruses, including HDV, HBV, and HIV, along with preclinical candidates for influenza, COVID-19, RSV, and HPV. The firm collaborates with various industry leaders for research and development, enhancing its capabilities and market reach. Established in 2016 and based in San Francisco, it is positioned in the growing field of immunology.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
587
CEO
Dr. Marianne De Backer M.B.A., M.Sc., Ph.D.
Country
United States
IPO Year
2019
Website
www.vir.bioVir Biotechnology Inc (VIR) Latest News & Analysis
The global cancer therapeutics market is projected to surpass $400 billion by 2028, with frequent FDA and EMA approvals of new anticancer drugs. Investors should exercise caution.
The growing cancer therapeutics market, projected to exceed $400 billion by 2028, signals significant investment opportunities and potential volatility in pharmaceutical stocks.
Vir Biotechnology's stock surged 62% following positive results for two cancer treatments announced on Wednesday.
Vir Biotechnology's significant stock surge indicates strong investor confidence driven by positive clinical results, potentially leading to increased market share and future revenue growth in cancer treatments.
Vir Biotechnology's stock rose after the company released initial Phase 1 data for two T-cell engagers, VIR-5818 for HER2 tumors and VIR-5500 for mCRPC.
Vir Biotechnology's positive Phase 1 data for VIR-5818 and VIR-5500 indicates potential breakthroughs in cancer treatment, likely boosting investor confidence and stock value.
Vir Biotechnology, Inc. presented initial Phase 1 data for two T-cell engagers: VIR-5818 for HER2-expressing tumors and VIR-5500 for metastatic castration-resistant prostate cancer.
Initial Phase 1 data on VIR-5818 and VIR-5500 could signal potential breakthroughs in cancer treatment, influencing Vir Biotechnology's stock performance and investor sentiment.
Vir Biotechnology reported positive initial data from Phase I trials for VIR-5818 and VIR-5500 in heavily pretreated patients with solid tumors.
Encouraging results from VIR-5818 and VIR-5500 may indicate potential for new cancer treatments, possibly boosting Vir Biotechnology's stock value and attracting investor interest.
Vir Biotechnology presented initial Phase 1 data for two T-cell engagers, VIR-5818 and VIR-5500, showing promising safety and efficacy with no dose-limiting cytokine release syndrome reported.
Initial Phase 1 data from Vir Biotechnology's T-cell engagers shows promising safety and efficacy, boosting potential for treatment options in cancer, which could enhance market valuation and investor interest.
Frequently Asked Questions About VIR Stock
What is Vir Biotechnology Inc's (VIR) stock forecast for 2025?
Based on our analysis of 14 Wall Street analysts, Vir Biotechnology Inc (VIR) has a median price target of $20.00. The highest price target is $110.00 and the lowest is $14.00.
Is VIR stock a good investment in 2025?
According to current analyst ratings, VIR has 7 Buy ratings, 2 Hold ratings, and 0 Sell ratings. The stock is currently trading at $10.53. Always conduct your own research and consider your investment goals before making investment decisions.
What is the price prediction for VIR stock?
Wall Street analysts predict VIR stock could reach $20.00 in the next 12 months. This represents a 89.9% increase from the current price of $10.53. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Vir Biotechnology Inc's business model?
The company operates by developing therapeutic products aimed at treating and preventing serious infectious diseases. It generates revenue through a combination of grant agreements, collaborative research, licensing deals, and partnerships with various organizations, including prominent foundations and pharmaceutical companies.
What is the highest forecasted price for VIR Vir Biotechnology Inc?
The highest price target for VIR is $110.00 from Patrick Trucchio at HC Wainwright & Co., which represents a 944.6% increase from the current price of $10.53.
What is the lowest forecasted price for VIR Vir Biotechnology Inc?
The lowest price target for VIR is $14.00 from Eric Joseph at JP Morgan, which represents a 33.0% increase from the current price of $10.53.
What is the overall VIR consensus from analysts for Vir Biotechnology Inc?
The overall analyst consensus for VIR is bullish. Out of 14 Wall Street analysts, 7 rate it as Buy, 2 as Hold, and 0 as Sell, with a median price target of $20.00.
How accurate are VIR stock price projections?
Stock price projections, including those for Vir Biotechnology Inc, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
